Circulating miR-200 family and CTCs in metastatic breast cancer before, during, and after a new line of systemic treatment
The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 August 2022
|
| In: |
International journal of molecular sciences
Year: 2022, Jahrgang: 23, Heft: 17, Pages: 1-12 |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms23179535 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms23179535 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/23/17/9535 
|
| Verfasserangaben: | Chiara Fischer, Andrey Turchinovich, Manuel Feisst, Fabian Riedel, Kathrin Haßdenteufel, Philipp Scharli, Andreas D. Hartkopf, Sara Y. Brucker, Laura Michel, Barbara Burwinkel, Andreas Schneeweiss, Markus Wallwiener and Thomas M. Deutsch |
| Zusammenfassung: | The extracellular circulating microRNA (miR)-200 regulates epithelial-mesenchymal transition and, thus, plays an essential role in the metastatic cascade and has shown itself to be a promising prognostic and predictive biomarker in metastatic breast cancer (MBC). Expression levels of the plasma miR-200 family were analyzed in relationship to systemic treatment, circulating tumor cells (CTC) count, progression-free survival (PFS), and overall survival (OS). Expression of miR-200a, miR-200b, miR-200c, miR-141, and miR-429, and CTC status (CTC-positive ≥ 5 CTC/7.5 mL) was assessed in 47 patients at baseline (BL), after the first completed cycle of a new line of systemic therapy (1C), and upon the progression of disease (PD). MiR-200a, miR-200b, and miR-141 expression was reduced at 1C compared to BL. Upon PD, all miR-200s were upregulated compared to 1C. At all timepoints, the levels of miR-200s were elevated in CTC-positive versus CTC-negative patients. Further, heightened miR-200s expression and positive CTC status were associated with poorer OS at BL and 1C. In MBC patients, circulating miR-200 family members decreased after one cycle of a new line of systemic therapy, were elevated during PD, and were indicative of CTC status. Notably, increased levels of miR-200s and elevated CTC count correlated with poorer OS and PFS. As such, both are promising biomarkers for optimizing the clinical management of MBC. |
|---|---|
| Beschreibung: | Gesehen am 20.10.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1422-0067 |
| DOI: | 10.3390/ijms23179535 |